<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FEF34897-0AF2-422B-8B10-C1949C0FDFBF"><gtr:id>FEF34897-0AF2-422B-8B10-C1949C0FDFBF</gtr:id><gtr:name>Oxleas NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pinewood House</gtr:line1><gtr:line2>Pinewood Place</gtr:line2><gtr:postCode>DA2 7WG</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C4AE6001-1347-4246-84A7-81408473BD3B"><gtr:id>C4AE6001-1347-4246-84A7-81408473BD3B</gtr:id><gtr:name>Royal Cornwall Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Royal Cornwall Hospital</gtr:line1><gtr:line2>Treliske</gtr:line2><gtr:postCode>TR1 3LJ</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D4147631-112B-45C7-8654-88569CA5A5B8"><gtr:id>D4147631-112B-45C7-8654-88569CA5A5B8</gtr:id><gtr:name>Devon Partnership NHS Trust</gtr:name><gtr:address><gtr:line1>Devon Partnership NHS Trust</gtr:line1><gtr:line2>Wonford House Hospital</gtr:line2><gtr:line3>Dreyden Road</gtr:line3><gtr:postCode>EX2 5AF</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E0A0623-0E39-4BC1-BF32-2B3F7240DFB5"><gtr:id>4E0A0623-0E39-4BC1-BF32-2B3F7240DFB5</gtr:id><gtr:name>South West London and St George's Mental Health NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Psychosis Studies</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FEF34897-0AF2-422B-8B10-C1949C0FDFBF"><gtr:id>FEF34897-0AF2-422B-8B10-C1949C0FDFBF</gtr:id><gtr:name>Oxleas NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pinewood House</gtr:line1><gtr:line2>Pinewood Place</gtr:line2><gtr:postCode>DA2 7WG</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C4AE6001-1347-4246-84A7-81408473BD3B"><gtr:id>C4AE6001-1347-4246-84A7-81408473BD3B</gtr:id><gtr:name>Royal Cornwall Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Royal Cornwall Hospital</gtr:line1><gtr:line2>Treliske</gtr:line2><gtr:postCode>TR1 3LJ</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D4147631-112B-45C7-8654-88569CA5A5B8"><gtr:id>D4147631-112B-45C7-8654-88569CA5A5B8</gtr:id><gtr:name>Devon Partnership NHS Trust</gtr:name><gtr:address><gtr:line1>Devon Partnership NHS Trust</gtr:line1><gtr:line2>Wonford House Hospital</gtr:line2><gtr:line3>Dreyden Road</gtr:line3><gtr:postCode>EX2 5AF</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E0A0623-0E39-4BC1-BF32-2B3F7240DFB5"><gtr:id>4E0A0623-0E39-4BC1-BF32-2B3F7240DFB5</gtr:id><gtr:name>South West London and St George's Mental Health NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/375C39D9-88B9-40AF-B8E8-A7261E1A12C8"><gtr:id>375C39D9-88B9-40AF-B8E8-A7261E1A12C8</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Stone</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7C915C69-5A8B-4659-903B-EA34A76F70D2"><gtr:id>7C915C69-5A8B-4659-903B-EA34A76F70D2</gtr:id><gtr:firstName>Gareth</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Barker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/61FCED78-87E1-4671-88B2-84296826EB55"><gtr:id>61FCED78-87E1-4671-88B2-84296826EB55</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:surname>McGuire</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1251CEE5-B937-47CD-87DE-8DCAA5A22BDF"><gtr:id>1251CEE5-B937-47CD-87DE-8DCAA5A22BDF</gtr:id><gtr:firstName>Fernando</gtr:firstName><gtr:otherNames>Osmin</gtr:otherNames><gtr:surname>Zelaya</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FAE7ECEE-6B22-45F9-89B9-D57AB4A1FE64"><gtr:id>FAE7ECEE-6B22-45F9-89B9-D57AB4A1FE64</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Hunter</gtr:otherNames><gtr:surname>MacCabe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/337C830B-27CB-4397-8E2C-49C2E7486172"><gtr:id>337C830B-27CB-4397-8E2C-49C2E7486172</gtr:id><gtr:firstName>Alice</gtr:firstName><gtr:surname>Egerton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/93DFBBCC-4BFF-4D72-A55A-C63D84DD645B"><gtr:id>93DFBBCC-4BFF-4D72-A55A-C63D84DD645B</gtr:id><gtr:firstName>Oliver</gtr:firstName><gtr:surname>Howes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL003988%2F1"><gtr:id>3E1752B8-A69A-4CE5-A110-0CD22AAE7D0E</gtr:id><gtr:title>Neurobiology of response to clozapine in treatment resistant schizophrenia</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L003988/1</gtr:grantReference><gtr:abstractText>The aim of this research is to understand how Clozapine, a drug used to treat schizophrenia, produces its therapeutic effects. Clozapine is normally only used in very unwell patients, who have already tried other medications which have not worked. This is because, although clozapine is the most effective treatment for schizophrenia, it can also cause serious side effects. Patients taking clozapine are therefore closely monitored, including having regular blood tests. Unfortunately clozapine is only effective in reducing symptoms in about half of patients who try it, and there are very few treatment options left for patients who do not do well on clozapine. For these reasons, many doctors and patients put-off trying clozapine, only using it as a last resort. During this delay, patients are often treated instead with high doses of other medications or several medications in combination, which is not proven to be a good strategy and may also be harmful. At the moment, it is unknown how clozapine produces its therapeutic effects and why it works better in some people than in others. 

In this project, we will try and understand the biology behind the therapeutic effects of clozapine. We hope that understanding the biology will help scientists develop new medications as alternatives to clozapine, which could be used in patients who do not get better with clozapine or who experience bad side effects. We also hope that understanding the biology behind the effects of clozapine will help us to develop tests to predict in advance whether or not an individual patient is likely to get better with clozapine treatment. Such a test would mean that clozapine might be given earlier to patients who are likely to do well on it, while it could be avoided in patients who are unlikely to benefit. 

We think that the therapeutic effects of clozapine might be due to its ability to improve chemical signalling in the brain. On the basis of previous research, we are particularly interested in the effects of clozapine on two closely related chemicals which are vital for normal brain functioning - glutamate and GABA (gamma-amino-butyric-acid). We also think that the response to clozapine will be associated with specific patterns of blood flow in the brain. Using magnetic resonance imaging (MRI) brain scans, we are able to measure the amounts of glutamate and GABA and blood flow non-invasively in patients. 

In this project, we will use MRI scans to measure brain glutamate, GABA and perfusion in patients with schizophrenia before they start clozapine treatment and after they have been taking clozapine for 12 weeks, as part of their normal clinical care. We will assess each patients' symptoms before and after 12 weeks of clozapine to see how well their symptoms have improved. By looking at the changes in glutamate, GABA and blood flow in the brain which occur with clozapine treatment in relation to change in symptoms, we will better understand how clozapine produces its therapeutic effects. We will also be able to determine whether the level of glutamate, GABA and pattern of blood flow in the brain before starting clozapine can predict whether or not clozapine will improve symptoms in a particular patient.

We hope that this information will then be useful to developing new drugs for schizophrenia, for example drugs with greater effects on brain glutamate, GABA and blood flow. We also hope that this research could lead to tests, where MRI scans measuring glutamate, GABA and blood flow could help doctors decide whether or not clozapine might be effective in their individual patient, where a positive result would encourage them to try it earlier. In these ways, this research could improve the health of patients with schizophrenic illness.</gtr:abstractText><gtr:technicalSummary>The aim of this research is to understand the neurobiology of response to clozapine in treatment resistant schizophrenia (TRS), as this will aid future drug development and support earlier clozapine initiation in patients most likely to benefit. 

Our recent research suggests that TRS may be associated with increased glutamate levels in the anterior cingulate cortex, which may explain why dopaminergic antipsychotics fail in these patients. There is some evidence that clozapine may alter brain glutamatergic and GABAergic neurotransmission, but this has never been tested directly. 
We hypothesise that response to clozapine in TRS will be associated with increases in GABA, decreases in brain glutamate levels and decreases in regional brain perfusion. Our secondary hypothesis is that patients with the lowest GABA and perfusion and highest glutamate levels before starting clozapine will show the greatest response to treatment. 

The sample will include 60 patients with TRS. All data will be acquired before and after 12 weeks of clozapine treatment. Regional brain glutamate and GABA levels will be estimated using proton magnetic resonance spectroscopy (1H-MRS), and perfusion using pulsed continuous arterial spin labelling (pCASL) in a single MRI scanning session. Severity of schizophrenia symptoms will be assessed, primarily using the positive and negative syndrome scale. 

Analysis will determine the associations between changes in brain glutamate, GABA and perfusion levels and symptomatic response to clozapine. In a second analysis we will determine these neuroimaging variables at baseline are predictive of subsequent response, using multivariate pattern recognition analysis will be used to classify the cases according to clinical outcome (response versus non-response).

This research will aid the development of new (non-dopamiergic) antipsychotics, and biomarkers to predict response to clozapine or stratify patients in clinical trials of new drugs.</gtr:technicalSummary><gtr:potentialImpactText>The potential beneficiaries from this work are as follows:
1) PATIENT AND CARERS
The ultimate aim of this research is to improve treatment for people with schizophrenia. We hope to do this in several ways. 
First, by providing information for the rational development of new drugs to treat schizophrenia. This project specifically addresses a patient population who do not respond well to the currently available medications, and aims to find new targets for novel approaches. 
Second, this research will determine whether MRI scans can predict in advance whether or not a particular patient will respond to clozapine. This means that patients who will do well on clozapine could be given it earlier, while side effects could be avoided in those unlikely to benefit. This would ultimately improve the health of this patient group. Furthermore if the approach is successful, it could be applied to other medications or other mental health disorders. 
Third, if the MRI scans provide biomarkers of treatment response, this could be used to stratify patients in clinical trials which would expedite drug development for this group. 
Achieving these aims will require engagement with the pharmaceutical industry and academic community. 
2) ACADEMIC RESEARCH COMMUNITY
The ways in which the academic community will benefit from this research are included in the section 'Academic Beneficiaries'
3) INDUSTRY
As described above, it is hoped that this research will lead to new targets for drug development and biomarkers to stratify patients in clinical trials. New drug development in schizophrenia is currently a key focus for industry. 
4) CLINICIANS 
If information from MRI scans can be used to help predict response, this would aid clinical decision making in a difficult area. The decision to put a patient on clozapine is not easy, as clozapine may not work and is potentially associated with lethal adverse effects, thus requiring regular monitoring and resources. For this reason trials of clozapine are often delayed, and suboptimal treatment strategies employed meantime. If the availability of such a test could increase confidence that clozapine would be effective, this would help decision making and clinicians would be encouraged to try clozapine earlier. Likewise, if tests show clozapine was unlikely to be helpful in a particular patient, this would provide a rational basis for trying other options first.
6) GENERAL PUBLIC
This research addresses management of treatment resistant schizophrenia. These are among the most unwell of mental health patients, who require high health and social care resources, are over-represented in forensic psychiatry settings and who seldom return to work. Improving the health of this patient group will therefore have positive societal and socioeconomic effects.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>692268</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>South West London and St George's Mental Health NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Addition of South West London and St George's NHS Trust</gtr:description><gtr:id>42B2904B-76B7-44B1-B916-633222766427</gtr:id><gtr:impact>The collaboration has only recently commenced and there are no outcomes yet.</gtr:impact><gtr:outcomeId>56d80d8bddf926.44293250-1</gtr:outcomeId><gtr:partnerContribution>To identify potential study participants</gtr:partnerContribution><gtr:piContribution>The collaboration is to increase participant recruitment to the research study. Our contribution is to recruit and assess patients. The NHS Trust benefits from becoming further involved with research activity.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Collaboration with EU-FP7 CRESTAR</gtr:description><gtr:id>788D8C5E-67B0-4129-B781-3BD6178B3CD3</gtr:id><gtr:impact>This collaboration has led to a joint PhD student combining data from both projects, in examining genetic influences on brain structure in schizophrenia and how this relates to clozapine response. I am first supervisor, the local CRESTAR PI (Dr James MacCabe) is second supervisor.</gtr:impact><gtr:outcomeId>5460a1ca7eb306.92289476-1</gtr:outcomeId><gtr:partnerContribution>The CRESTAR research team are contributing to data collection to our MRC study (participant recruitment, imaging measures, clinical assessment).</gtr:partnerContribution><gtr:piContribution>One workpackage of the CRESTAR study collects blood samples for epigenetic and genetic markers of treatment resistant schizophrenia and clozapine response. The MRC and CRESTAR study teams are collaborating as we are investigating the same patient group. This means there is increased staff resource for both studies, and that in analysis it will be possible to relate the MRC dataset (brain imaging, clinical measures) and CRESTAR data (genetics, epigenetics) in the same individuals, to provide further information on biological mechanisms of clozapine response. 

Myself and my research team are contributing to data collection for CRESTAR (participant recruitment, taking blood samples, clinical assessment)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxleas NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Addition of Oxleas NHS trust as a research site</gtr:description><gtr:id>F0840E12-6CF2-4DB3-A12B-BF184C19B7D9</gtr:id><gtr:impact>The collaboration has only just commenced, there are no outcomes yet.</gtr:impact><gtr:outcomeId>56d80cdce540a5.22382139-1</gtr:outcomeId><gtr:partnerContribution>Identification of potential study participants</gtr:partnerContribution><gtr:piContribution>The purpose of the partnership is to increase participant recruitment to the research study. Our contribution is to recruit and assess the participants. Oxleas will benefit by becoming further involved in research activity.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Devon Partnership NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Addition of Devon NHS trust as recruitment site</gtr:description><gtr:id>3BFD380D-E9F5-4191-AEB3-F54A0FF2DE1E</gtr:id><gtr:impact>It is expected this site will recruit additional participants to the study (blood based biomarkers and clinical data only).</gtr:impact><gtr:outcomeId>58c6b316623c91.13960401-1</gtr:outcomeId><gtr:partnerContribution>Recruitment and assessment of study participants</gtr:partnerContribution><gtr:piContribution>Addition of Devon NHS trust as recruitment site</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Cornwall Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Addition of Royal Cornwall NHS Trusts</gtr:description><gtr:id>8E8FCD83-B57F-4930-A5ED-FB7E2E976592</gtr:id><gtr:impact>We expect this site will contribute further participants to the study (blood-based biomarkers and clinical data only).</gtr:impact><gtr:outcomeId>58c6b29b1c0180.75228263-1</gtr:outcomeId><gtr:partnerContribution>Recruitment and assessment of participants</gtr:partnerContribution><gtr:piContribution>Addition of further recruitment site to this study</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation of the study to South London and St George's NHS Trust</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0D328D6B-87EF-4146-AF9D-731461F1D968</gtr:id><gtr:impact>The purpose was to present the study to clinical teams within South London and St George's NHS Trust, to increase awareness of the research and aid participant recruitment to the study. Several people reported interest and were keen to be involved.</gtr:impact><gtr:outcomeId>56d813dc73df92.91888397</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation of study at ECNP targeted network meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4475588B-6BA7-4DB8-A85C-3F34049F8F56</gtr:id><gtr:impact>The study was part of a larger discussion on schizophrenia research amongst academic leaders in this area

Interest in study from International researchers</gtr:impact><gtr:outcomeId>5460a5fe1249d6.07106837</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Association for Psychopharmacology Summer Meeting 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6A251F6C-DAC6-47AE-8491-C3CCF36B58F7</gtr:id><gtr:impact>The research was presented at a conference during a symposium on glutamate in psychiatric disorders</gtr:impact><gtr:outcomeId>56d812a08a4ea2.44145835</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation of the study to MSc students</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C0E679F6-0E7F-42DD-8B1C-AA07DA8E539D</gtr:id><gtr:impact>The study was presented to students currently on the MSc in Psychiatric Research at KCL. The purpose was to highlight the on-going research as a topical and important area and engage students with the topic. The presentation stimulated several questions and an interesting debate. Three students are becoming involved with research related to the study.</gtr:impact><gtr:outcomeId>56d8148774f2b1.51572405</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation of the study to clinical teams</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8F3EDF45-06FB-4AEF-9AF2-885E25AB8AC3</gtr:id><gtr:impact>The talks have led to discussion of the importance of the research area, and practical considerations which have fed back into the research approach
The talks have increased visibility of the study and led to clinical teams putting forward patients to participate in the research


There have been an increased number of patient referrals</gtr:impact><gtr:outcomeId>5460a337585301.04312481</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation of the study to pharmacists</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E43BEF11-4551-426D-A1F8-1394B4C13C7E</gtr:id><gtr:impact>The talk led to provision of a system for referring potential study participants through ward pharmacists

Increase in number of referrals through pharmacy</gtr:impact><gtr:outcomeId>5460a414b9c536.54101158</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation of study to Oxleas NHS trust</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2F180BCD-A465-4353-BC2F-C30002E8B9A3</gtr:id><gtr:impact>The research study has been presented to clinical teams within Oxleas NHS trust to increase awareness and aid recruitment to the study</gtr:impact><gtr:outcomeId>56d813592be426.90417946</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>68000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Extension</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2DB3DB41-3CEC-47D1-83D5-37092A25182E</gtr:id><gtr:outcomeId>58c6c1fbd9b586.45878736</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1176581</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Stratified Medicine Initiative</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L011794/1</gtr:fundingRef><gtr:id>7A833F03-D3CF-472C-9CC0-7F0EE5365AC8</gtr:id><gtr:outcomeId>56d8317dab8227.73072624</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>12500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Biomedical Research Centre for Mental Health and Dementia Unit (BRC/U)</gtr:department><gtr:description>BRC NIHR funding (Internal)</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>7F343D0F-CA8F-46EF-B17E-D819AFF86AB6</gtr:id><gtr:outcomeId>56d82f04ef7ea3.89621265</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Biomedical Research Centre for Mental Health and Dementia Unit (BRC/U)</gtr:department><gtr:description>BRC NIHR pilot MRI (internal)</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>BF911320-AF7D-4E94-A444-F9AA6E21163A</gtr:id><gtr:outcomeId>56d82f6b712df9.27774872</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>PhD training</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>EC3D7540-BB06-409A-9EDB-80A5FF804E9B</gtr:id><gtr:impact>We host three PhD students who are doing research related to this project</gtr:impact><gtr:outcomeId>56e14784a6cb35.46867229</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MSc student training</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>070A6201-53CA-40B2-8CC5-F8474A58D2AA</gtr:id><gtr:impact>We host 4 MSc students who are performing there dissertation projects related to this research</gtr:impact><gtr:outcomeId>56e147d5969e87.37110445</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>We have developed an electronic case report form (eCRF) for all participants in the study This is used for collection of clinical data, and linking clinical records to MRI scans and blood samples. The data is anonymised prior to entry. 
This will streamline data collection, analysis and data sharing at the end of the project
The eCRF contains modules for assessment instruments which can be easily exported / modified for other projects involving this patient group</gtr:description><gtr:id>E5F7C4D5-9091-48A9-9972-7528CC81662E</gtr:id><gtr:impact>The eCRF was shared with the recently funded MRC Stratified Medicine multicentre UK study STRATA (PI Kapur). The database will greatly aid data collection, analysis and sharing in STRATA and other future projects.</gtr:impact><gtr:outcomeId>54610226637fc6.78655391</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Psychosis eCRF (RedCAP)</gtr:title><gtr:type>Data handling &amp; control</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>This is a software toolbox that has been developed for automated processing of brain MRI arterial spin labelling (ASL) perfusion images, by Dr Zelaya a co-investigator on the grant. It will be used to process the images acquired in the research study and we have an MSc student currently working on this analysis.</gtr:description><gtr:id>31DA70B2-0702-46F5-A1B5-8D88D7434053</gtr:id><gtr:impact>This has been published (see doi below). We are hosting an MSc student who is performing a preliminary analysis of the study data using this software as the basis of her dissertation project</gtr:impact><gtr:outcomeId>56d8288008af46.72488570</gtr:outcomeId><gtr:title>ASAP (Automatic Software for ASL Processing)</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F7BB7C96-C36C-4810-AEAD-442C67104AB3</gtr:id><gtr:title>Glutamate in Psychosis: A Meta-Analysis of Proton Magnetic Resonance Spectroscopy (1H-MRS) Studies</gtr:title><gtr:parentPublicationTitle>JAMA Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e79177d0024e201f89a6a3dd1b859416"><gtr:id>e79177d0024e201f89a6a3dd1b859416</gtr:id><gtr:otherNames>Merritt K</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>56d83ae63af4e3.10851619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81AD223C-F68F-485B-9335-6159BD9E28F2</gtr:id><gtr:title>Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93ea0bb91d90325b6e0539f945e0a739"><gtr:id>93ea0bb91d90325b6e0539f945e0a739</gtr:id><gtr:otherNames>Lally J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>58c6b1bd6b2d69.67418224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7852F32E-06DD-4DF3-9F87-3457553CE7B3</gtr:id><gtr:title>Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a21171759e684b9c867ad92deb68c78c"><gtr:id>a21171759e684b9c867ad92deb68c78c</gtr:id><gtr:otherNames>Mouchlianitis E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>56d8113863b131.90370907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>161520D6-9C5E-4D0E-A48F-D2E7B27259EF</gtr:id><gtr:title>Neuroanatomical changes in people with high schizotypy: relationship to glutamate levels.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14b4c0a6b15f22e1b9e8682528fa2337"><gtr:id>14b4c0a6b15f22e1b9e8682528fa2337</gtr:id><gtr:otherNames>Modinos G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>5aa1517aa7de17.31355122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D19DC75-F971-47FF-A3B9-F2D340543462</gtr:id><gtr:title>Corticolimbic hyper-response to emotion and glutamatergic function in people with high schizotypy: a multimodal fMRI-MRS study.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14b4c0a6b15f22e1b9e8682528fa2337"><gtr:id>14b4c0a6b15f22e1b9e8682528fa2337</gtr:id><gtr:otherNames>Modinos G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>5a35e3d4cfb541.57216515</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0936C722-25E7-41AE-83DE-414224DFC729</gtr:id><gtr:title>Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.</gtr:title><gtr:parentPublicationTitle>JAMA psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e79177d0024e201f89a6a3dd1b859416"><gtr:id>e79177d0024e201f89a6a3dd1b859416</gtr:id><gtr:otherNames>Merritt K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-622X</gtr:issn><gtr:outcomeId>585d721fd93ee1.41404114</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9142BFA7-7CB2-4171-8476-AA785372ED4F</gtr:id><gtr:title>Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a79e5d2d5d5dfbe5a7d92af4cf5c830a"><gtr:id>a79e5d2d5d5dfbe5a7d92af4cf5c830a</gtr:id><gtr:otherNames>Egerton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>5aa1517ae40395.07498289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3253DD5-18CA-43E6-BB4A-BA2FFD94A975</gtr:id><gtr:title>Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review.</gtr:title><gtr:parentPublicationTitle>BMC psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2bc258fc6a9fb7037c8a906cbf25459"><gtr:id>d2bc258fc6a9fb7037c8a906cbf25459</gtr:id><gtr:otherNames>Gillespie AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-244X</gtr:issn><gtr:outcomeId>58c6b1bc763e37.70061866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B14C766B-ED21-44A9-8C07-3F7F919F6BC3</gtr:id><gtr:title>Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93ea0bb91d90325b6e0539f945e0a739"><gtr:id>93ea0bb91d90325b6e0539f945e0a739</gtr:id><gtr:otherNames>Lally J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>56d8113ad200b3.91263144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5BFC4D6-3B31-4358-8A53-19A435660D1C</gtr:id><gtr:title>Effects of Antipsychotic Administration on Brain Glutamate in Schizophrenia: A Systematic Review of LongitudinalH-MRS Studies.</gtr:title><gtr:parentPublicationTitle>Frontiers in psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a79e5d2d5d5dfbe5a7d92af4cf5c830a"><gtr:id>a79e5d2d5d5dfbe5a7d92af4cf5c830a</gtr:id><gtr:otherNames>Egerton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-0640</gtr:issn><gtr:outcomeId>5a2fd7bc3bb804.02194490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EA8DEC0-6099-4DF5-B4DC-BA123AD6714E</gtr:id><gtr:title>ASAP (Automatic Software for ASL Processing): A toolbox for processing Arterial Spin Labeling images.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87fe7b75360b2d376d82e8da9355c9c6"><gtr:id>87fe7b75360b2d376d82e8da9355c9c6</gtr:id><gtr:otherNames>Mato Abad V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0730-725X</gtr:issn><gtr:outcomeId>56d8113c507929.26845258</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L003988/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>